Impact of Treatments on Diabetic Control and Gastrointestinal Symptoms after Total Pancreatectomy

Maarten R. Struyvenberg, Zhi Ven Fong, Camilia R. Martin, Jennifer F. Tseng, Thomas E. Clancy, Carlos Fernández-Del Castillo, Hanna J. Tillman, Melena D Bellin, Steven D. Freedman

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Objectives The aims of this study were to compare the safety, efficacy, and patients' quality of life with continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDIs) in type 3c diabetes mellitus (T3cDM) following total pancreatectomy (TP) and pancreatic enzyme usage. Methods Thirty-nine patients with T3cDM (18 CSII patients vs 21 MDI patients) who underwent TP between 2000 and 2016 at 3 Harvard-affiliated hospitals and the University of Minnesota returned prospectively obtained questionnaires examining quality of life and both endocrine and exocrine pancreatic functions. Results Main indications for TP were as follows: chronic pancreatitis (n = 19), intraductal papillary mucinous neoplasm (n = 12), and adenocarcinoma (n = 4). Median hemoglobin A1c using MDIs was 8.1% versus 7.3% in CSII. Severe hypoglycemic events using MDIs were increased compared with CSII (P = 0.02). There were no significant differences in quality-of-life measures with CSII versus MDIs. Pancreatic enzyme dose per meal (P < 0.05) differed between the hospitals. Gastrointestinal symptoms and unintended weight loss (P < 0.01) were more common with low doses of pancreatic enzymes. Conclusions After TP, CSII therapy is safe compared with MDIs in T3cDM and not associated with an increase in severe hypoglycemic events. Pancreatic enzyme replacement therapy is highly variable with low doses associated with unintentional weight loss and gastrointestinal symptoms.

Original languageEnglish (US)
Pages (from-to)1188-1195
Number of pages8
Issue number9
StatePublished - Oct 1 2017

Bibliographical note

Funding Information:
This work was conducted with support from Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health award UL1 TR001102) and financial contributions from Harvard University and its affiliated academic health care centers.


  • exocrine pancreatic insufficiency
  • gastrointestinal symptoms
  • insulin pump
  • pancreatectomy
  • pancreatic enzymes

Fingerprint Dive into the research topics of 'Impact of Treatments on Diabetic Control and Gastrointestinal Symptoms after Total Pancreatectomy'. Together they form a unique fingerprint.

Cite this